"As a result of these limitations, these findings add little to the current evidence," Fonarow concluded. "Beta blockers continue to be guideline-recommended and should continue to be prescribed for patients long-term after a heart attack."
More information
To learn more about heart disease, visit the American Heart Association.
Copyright © 2012 HealthDay. All rights reserved.
Reader Comments (